Children's Medical Center Corporation

Steven L Swendeman

Timothy T Hla

Mark Puder

Lois Elaine Smith

Teresa Sanchez

Annarita DiLorenzo

Theresa Sanchez

Provided herein are methods of treating lung disease using fusion proteins comprising ApoM (e.g., human or murine ApoM) fused to a constant region (Fc) of a immunoglobulin G (IgG, e.g., human IgG or murine IgG).

ApoM-Fc fusion proteins for treating lung diseases

The present disclosure is directed to an engineered phospholipid or lysophospholipid (e.g., sphingosine 1-phosphate (S1P)) chaperone derived from an Apolipoprotein M (ApoM)-Fc fusion protein having an extended half life in vivo. The disclosed ApoM-Fc fusion protein provides a safe, efficient and effective means of delivering S1P to endothelial cells and to all tissues of the body.

ApoM-Fc fusion proteins, complexes thereof with sphingosine 1-phosphate (S1P), and methods for treating vascular and non-vascular diseases

Growing community of inventors

Cambridge, MA, United States of America

Steven L Swendeman